Skip to main content
. 2021 Aug 3;280:114488. doi: 10.1016/j.jep.2021.114488

Table 2.

Potency value and content of active compounds.

NO. Compound Target EC50/IC50 (μM) Agonist/antagonist Content μg/mg
1 licochalcone B GPR35 25.12 agonist 0.000822
2 tectorigenin GPR35 >200 agonist 0.004408
3 taxifolin GPR35 >200 agonist 0.000486
4 isochlorogenic acid C GPR35 114.30 agonist 0.183710
5 isoliquiritigenin GPR35 >200 agonist 0.000073
6 baicalin GPR35 >200 agonist 2.571457
7 scutellarin GPR35 86.26 agonist 0.171974
8 caffeic acid GPR35 290 a agonist 0.0344684
9 gallic acid GPR35 1.16 a agonist 0.008892
10 baicalein GPR35 10.3 a agonist 0.003157
11 luteolin GPR35 7.24 a agonist 0.001091
12 quercetin GPR35 8.02 a agonist 0.003465
13 kynurenic acid GPR35 152 a agonist 0.008850
14 atractyline CB2 65.23 agonist undetected
15 shogaol H1 >200 antagonist undetected
1 licochalcone B B2 139.70 antagonist 0.000822
16 alisol A B2 >200 antagonist 0.001993
5 isoliquiritigenin B2 >200 antagonist 0.000073
17 ephedrine β2-adrenoceptor 0.49 agonist 1.391095
18 pseudoephedrine β2-adrenoceptor 9.00 agonist 0.823086
19 synephrine β2-adrenoceptor 0.25 agonist 0.162534
2 tectorigenin M3 >200 antagonist 0.0044075
20 aristofone M3 >200 antagonist undetected

The superscript letter a in column four indicates that the EC50/IC50 value measured using the DMR technique comes from literatures.